FinSMEs
Plexium Raises $102M Financing
Plexium
First Investment: 2018
Targeted protein degradation (TPD) is a way to inhibit or modulate the function of disease-causing proteins that aren’t druggable using conventional small molecules. Plexium is using a proprietary high-throughput cell screening technology to explore a variety of potential next-generation approaches to TPD, from monovalent protein degraders to molecular glues to novel E3 ligases. With partners, and on its own, the company is developing TPD drugs to fight cancer, central nervous system diseases, and other conditions.
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules